IMR Press / CEOG / Volume 38 / Issue 2 / pii/1630488776174-1176154937

Clinical and Experimental Obstetrics & Gynecology (CEOG) is published by IMR Press from Volume 46 Issue 1 (2019). Previous articles were published by another publisher on a subscription basis, and they are hosted by IMR Press on as a courtesy and upon agreement with S.O.G.

Open Access Original Research
Efficacy of vaginal use of topical estriol in postmenopausal women with urogenital atrophy
Show Less
1 Gynecology Department, Universidade Federal de Sao Paulo (EPM-UNIFESP), Sao Paulo, SP (Brazil)
Clin. Exp. Obstet. Gynecol. 2011, 38(2), 143–145;
Published: 10 June 2011

Objective: This study evaluates the effect of intravaginal estriol on urogenital atrophy, Pap smear parameters, colposcopy parameters and discomfort during gynecological examination. Methods: 31 postmenopausal women who had not used hormone therapy in the previous six months were studied. All women used intravaginal estriol, 1 mg/day for 21 days. The following variables were analyzed before and after treatment: complaints of urogenital atrophy; cytological parameters, colposcopic parameters, and subjective evaluation of discomfort during gynecologic examination. Results: All urogenital atrophy complaints improved after treatment. At the first visit, 45.2% of women presented a predominance of profound cells, 5 1.6% with predominance of intermediate cells, and 3.2% with predominance of superficial cells. At the second visit, these rates were 35.5%, 64.5%, and 0%, respectively. Evaluation of the maturation index showed that 83.9% of women had atrophic Pap smears, and 16. l % showed good estrogenic level before treatment. At the second visit, atrophic smears occurred in 12.9%, and 87.1 % of women exhibited good estrogenic level (x2 = 20.045; p = 0.000). Colposcopy showed that 71% of women had atrophic colpitis and/or petequiae before treatment, while atrophy after therapy was present in only 6.4%. The evaluation of other colposcopic parameters also improved after treatment. Great discomfort was reported by 19.4% before and by 0% after treatment. Conclusion: Intravaginal estriol 1 mg/day for a period of 21 days was efficient in improving urogenital atrophy, Pap smear parameters and colposcopic evaluation in postmenopausal women.
Vaginal smears
Post menopause
Topical estrogen therapy
Back to top